Shree Ganesh Biotech (India) Ltd.

As of June 30, 2026, Shree Ganesh Biotech (India) Ltd. carries a market capitalization of 227.22M, placing it among publicly traded companies globally. Its enterprise value stands at 227.22M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Shree Ganesh Biotech (India) Ltd. has 398.62M shares outstanding.

These figures are as of June 30, 2026.

These figures are as of June 30, 2026. The EV/Sales ratio of 4.53 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 227.22M versus a market cap of 227.22M, with the gap driven by net debt and cash on the balance sheet.

These figures cover the twelve months ended June 30, 2026. The company generates approximately 10.03M in revenue per employee across its workforce of 5.00, a quick read on workforce productivity versus industry peers.

As of the close on October 23, 2026, Shree Ganesh Biotech (India) Ltd.'s stock has declined approximately 41.33% over the past 52 weeks. The 50-day moving average sits at 0.49, while the 200-day moving average is 0.57.

Over the twelve months ended June 30, 2026, Shree Ganesh Biotech (India) Ltd. generated 50.17M in revenue and converted that into -3.86M in net income, yielding earnings per share of -0.01. EBITDA reached -17.63M, while operating income came in at -17.63M.

Over the twelve months ended June 30, 2026, Shree Ganesh Biotech (India) Ltd. posted a gross margin of -15.67, reflecting its pricing power and cost economics. The operating margin of -35.14 and net profit margin of -7.70 provide insight into operational efficiency.

Shree Ganesh Biotech (India) Ltd.'s most recent stock split took place on April 27, 2022 with a 1:2 split ratio.